The Journal of Urology · 1990 · 21 citations · 12 references
MedicineOncologySurgeryGenitourinary OncologySurgical OncologyUrologic OncologyBladder CancerMalignant NeoplasmsUpper Urinary Tract Cancer SurgeryMuscle-invasive Bladder Cancer Therapy
Reports of a dramatic decrease in tumor recurrence and regression of muscle invasive disease with oral bacillus Calmette-Guerin prompted us to conduct a randomized prospective comparison of oral bacillus Calmette-Guerin with the standard intravesical plus percutaneous therapy. Oral therapy consisted of 200 mg. Tice bacillus Calmette-Guerin 3 times each week. Intravesical and percutaneous Tice bacillus Calmette-Guerin at a dose of 50 mg. was given weekly for 6 weeks, at 8, 10 and 12 weeks, then at 6 months and every 6 months thereafter. Minimal side effects confirmed the safety of oral bacillus Calmette-Guerin. Tumor recurrence was documented in 21 of 33 oral bacillus Calmette-Guerin patients (64%) and 18 of 55 (33%) who received intravesical plus percutaneous therapy (p less than 0.002, chi-square test). We were unable to demonstrate any antitumor activity of oral bacillus Calmette-Guerin in this study.
12
Intravesical and systemic chemotherapy of murine bladder cancer.
Mark S. Soloway · PubMed · 1977 · 182 citations
Medicine, Oncology, Pharmacology +12
Gary R. Klimpel, Christopher S. Henney · The Journal of Immunology · 1978 · 90 citations
Studies on the mechanisms of action of BCG
I. Florentin, R. Huchet, M. Bruley-Rosset et al. · Cancer Immunology Immunotherapy · 1976 · 58 citations